NCAM1 and neoplasm: According to the WHO neuroendocrine tumors of the thymus typically exhibit strong, diffuse immunoreactivity for at least one neuroendocrine marker, such as chromogranin A, synaptophysin, CD56, and neuron-specific enolase (NSE), in more than 50% of tumor cells [9].